Skip to content

Ketamine: all studies

Page 410 of 448: studies 4,091 to 4,100 of 4,475, newest first. Back to the ketamine overview

Research

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Psychopharmacology 2022 Nina Schimmers, Joost J. Breeksema, Sanne Y Smith-Apeldoorn et al.

Terminally ill patients may experience existential distress, depression, or anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or pharmacological interventions have (time) limited efficacy. Psychedelic treatment may be a safe and effective alternative treatment option. Systematically review studies on psychedelic treatment with and without psychotherapy for...

The age of psychedelics

Journal of Psychopharmacology 2022 A. H. Young 3 citations

The 21st century has seen a dramatic flow and ebb in the fortunes of clinical psychopharmacology particularly with regard to antidepressants. For about 20 years, perhaps from about 1985 onwards, the tide flowed in with many ‘new’ drugs being made available to clinicians. In mood and psychotic disorders, these were essentially incremental advances from old drugs such as amitriptyline and...

New psychoactive substance cocktail in an intensive care intoxication case elucidated by molecular networking.

Clinical Toxicology 2022 Romain Pelletier, Brendan Le Daré, Loic Grandin et al. 22 citations

The recreational use of new psychoactive substances (NPS) is increasing worldwide. Among them, the arylcyclohexylamine family including phencyclidine (PCP) and ketamine derivatives is increasing. We report a non-fatal intoxication mainly due to arylcyclohexylamine compounds illustrated by molecular networking (MN). A 37-year-old man with a history of drug abuse was discovered with several bags...

DOI: 10.1080/15563650.2021.1931693 (opens in new tab) Full text (opens in new tab) New psychoactive substances Intensive care Intoxication Ketamine derivatives +1

[Identification of Three Arylcyclohexylamines (MXPr, MXiPr, and DMXE) in Illegal Products].

Yakugaku Zasshi 2022 Rie Tanaka, Maiko Kawamura, Sakumi Mizutani et al. 3 citations

Arylcyclohexylamines are a category of substances to which the anesthetic ketamine belongs. The arylcyclohexylamines have been reported to act as antagonists of the N-methyl-d-aspartate (NMDA) receptor. An analog of ketamine, 2-(ethylamino)-2-(3-methoxyphenyl)-cyclohexanone (methoxetamine; MXE), has been controlled as a narcotic in Japan and overdoses of MXE have been reported to cause health...

DOI: 10.1248/yakushi.21-00235 (opens in new tab) Full text (opens in new tab) Arylcyclohexylamine Deoxymethoxetamine Methoxisopropamine Methoxpropamine +1

Consciousness alterations in a cohort of young Swiss men: Associations with substance use and personality traits.

Frontiers in Psychiatry 2022 Marianthi Lousiana Deligianni, Joseph Studer, Gerhard Gmel et al. 1 citation

Substance-induced consciousness alterations (CA) have mainly been studied among users of psychedelics but not among people using street drugs. Explore occurrences of three different types of substance-induced CA [ego dissolution (ED), visual pseudo-hallucinations (VPH), anxiety/paranoia (A/P)] and their perceived influences on life, together with their associations with substance use and...

DOI: 10.3389/fpsyt.2022.1056159 (opens in new tab) Full text (opens in new tab) Personality Psychedelics Substance use Young men

Electroconvulsive therapy in treatment resistant depression: What is new?

Psychiatriki December 20, 2021 Styliani Kaliora 1 citation

Despite major advances in the treatment of mood disorders, major depression, a common mental disorder, remains a serious public health problem. Electroconvulsive therapy (ECT) regardless of the anesthetic agent used, is the most effective form of treatment in major depression and the gold standard therapy in treatment resistant depression. Ketamine is one of the anesthetic drugs approved by the...

Designs on Transcendence: Sketches of a TX machine

Foundations and Trends® in Human–Computer Interaction December 14, 2021 Mark Blythe, Elizabeth Buie 24 citations

Despite the vast number of people who use technology as a part of their spiritual practice, there is little research on the subject in studies of Human–Computer Interaction (HCI). Although HCI takes the idea of user experience very seriously, the field gives almost no consideration to experiences with technology that might be described as spiritual or transcendent. This paper reviews the work...

Novel drug developmental strategies for treatment‐resistant depression

British Journal of Pharmacology November 25, 2021 Éva Borbély, Mária Simon, Eberhard Fuchs et al. 103 citations

Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment‐resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1) knowledge of pathophysiology, (2) translational animal models and (3) objective diagnostic...

DOI: 10.1111/bph.15753 (opens in new tab) Depression economics Drug Pharmacology

Thermodynamic properties and Hilbert space of the human brain

arXiv Preprint Archive November 20, 2021 Dongmei Shi, Meng Li, Martin Walter et al. preprint

Any macrosystem consists of many microparticles. According to statistical physics, the macroproperties of a system are realized as the statistical average of the corresponding microproperties. In our study, a model based on ensemble theory from statistical physics is proposed. Specifically, the functional connectivity (FC) patterns confirmed by Leading Eigenvector Dynamics Analysis (LEiDA) are...

Full text (opens in new tab) Physics.bio-ph Nlin.cd

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression

CNS Drugs November 17, 2021 Susan Ling, Felicia Ceban, Leanna M.W. Lui et al. 123 citations

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and...